Humacyte (NASDAQ:HUMA – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Valuation and Earnings
This table compares Humacyte and MiNK Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Humacyte | $1.57 million | 412.62 | -$110.78 million | ($1.00) | -5.44 |
| MiNK Therapeutics | N/A | N/A | -$22.46 million | ($0.60) | -1.25 |
MiNK Therapeutics has lower revenue, but higher earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
Profitability
This table compares Humacyte and MiNK Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Humacyte | N/A | -942.81% | -79.04% |
| MiNK Therapeutics | N/A | N/A | -233.85% |
Analyst Recommendations
This is a summary of recent ratings for Humacyte and MiNK Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Humacyte | 0 | 1 | 4 | 1 | 3.00 |
| MiNK Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Humacyte presently has a consensus target price of $9.80, suggesting a potential upside of 80.15%. MiNK Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 1,100.00%. Given MiNK Therapeutics’ higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Humacyte.
Risk & Volatility
Humacyte has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
Summary
Humacyte beats MiNK Therapeutics on 7 of the 12 factors compared between the two stocks.
About Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
About MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
